PDCD1 and hepatocellular carcinoma: This process remodels the TIME and enhances the cytotoxic T‐cell‐mediated tumor immunotherapeutic effect, thereby overcoming resistance to anti‐PD‐1 therapy in residual tumor models of hepatocellular carcinoma following insufficient radiofrequency ablation.